Company intelligence / Profile preview
Aeolus Pharmaceuticals
- Ownership
- Private
- Development stage
- Phase 1
Overview
AEOL10150 completed a Phase I trial in healthy volunteers for safety/tolerability. The compound is being developed for both government biodefense procurement (as a medical countermeasure against radiation-induced lung injury) and commercial indications such as IPF and oncology. Preclinical data support efficacy in animal models for multiple indications. Additional compounds are at earlier stages or preclinical development.
- Therapeutic areas
- PulmonologyOncologyNeurology
- Modalities
- Small molecules (notably metalloporphyrins and antioxidant compounds)
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Aeolus Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aeolus Pharmaceuticals.